Peter Boer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Boer has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Hein A. Koomans
Department of Nephrology and Hypertension, University Medical Center Utrecht, The Netherlands
2 shared publicationsGerry Ligtenberg
Department of Nephrology, University Medical Center, Utrecht, The Netherlands
1 shared publication- Hein A. Koomans
Department of Nephrology, University Medical Center, Utrecht, The Netherlands
1 shared publication Hein Koomans
1 shared publicationInge H.T. Klein
Department of Nephrology, University Medical Center, Utrecht, The Netherlands
1 shared publicationJ. L. Tycho Vuurmans
Department of Nephrology and Hypertension, University Medical Center Utrecht, The Netherlands
1 shared publication
Latest Publications
- 1 May 2007
- Published by Wolters Kluwer Health in Hypertension
- Vol. 49 (5)
Response to Sympathetic Hyperactivity in Hypertensive Chronic Kidney Disease Patients Is Reduced During Standard Treatment
- 1 May 2007
- Published by Wolters Kluwer Health in Hypertension
- Vol. 49 (5)
Response to Sympathetic Hyperactivity in Hypertensive Chronic Kidney Disease Patients Is Reduced During Standard Treatment
- Open Access
- 24 August 2004
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (11) , 2742-2746
Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans
Background. In patients with renal or cardiac failure, renal function may be endangered by elevated plasma concentrations of the vasoconstrictor endothelin-1 (ET-1). To mimic effects of pathologically increased plasma ET-1, we gave intravenous ET-1 in healthy subjects and examined whether simultaneous infusion of the ETA-receptor antagonist VML 588 would prevent the effects of ET-1 on the kidney. Methods. Nine healthy men received on four separate days intravenous infusion of ET-1 (2.5 ng/kg/min) superimposed on vehicle (saline) or on VML 588 infusion (0.05, 0.20 and 0.40 mg/kg/h) in randomized order to assess the effects on renal function and renal haemodynamics. Results. At resting plasma ET-1, infusion of VML 588 alone had no significant effects on renal function. Infusion of ET-1 alone decreased glomerular filtration rate by 11% and this reduction was not reversed by co-infusion of VML 588. ET-1 reduced renal blood flow by 35% and VML 588 reduced this decrease by one-third, in a dose-independent fashion. ET-1 increased the filtration fraction by 34% and VML 588 reduced this increase dose-independently by one-half. ET-1 increased renal vascular resistance by 59% and VML 588 reduced this increase dose-independently by one-half. Finally, ET-1 decreased sodium excretion by 58% and VML 588 reduced this decrease dose-independently by two-thirds. Conclusions. ET-1-induced reductions in renal function were partially but not completely prevented in a dose-independent manner by the ETA-receptor antagonist VML 588.
- 24 August 2004
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (11) , 2742-2746
Open AccessEffects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans
Background. In patients with renal or cardiac failure, renal function may be endangered by elevated plasma concentrations of the vasoconstrictor endothelin-1 (ET-1). To mimic effects of pathologically increased plasma ET-1, we gave intravenous ET-1 in healthy subjects and examined whether simultaneous infusion of the ETA-receptor antagonist VML 588 would prevent the effects of ET-1 on the kidney. Methods. Nine healthy men received on four separate days intravenous infusion of ET-1 (2.5 ng/kg/min) superimposed on vehicle (saline) or on VML 588 infusion (0.05, 0.20 and 0.40 mg/kg/h) in randomized order to assess the effects on renal function and renal haemodynamics. Results. At resting plasma ET-1, infusion of VML 588 alone had no significant effects on renal function. Infusion of ET-1 alone decreased glomerular filtration rate by 11% and this reduction was not reversed by co-infusion of VML 588. ET-1 reduced renal blood flow by 35% and VML 588 reduced this decrease by one-third, in a dose-independent fashion. ET-1 increased the filtration fraction by 34% and VML 588 reduced this increase dose-independently by one-half. ET-1 increased renal vascular resistance by 59% and VML 588 reduced this increase dose-independently by one-half. Finally, ET-1 decreased sodium excretion by 58% and VML 588 reduced this decrease dose-independently by two-thirds. Conclusions. ET-1-induced reductions in renal function were partially but not completely prevented in a dose-independent manner by the ETA-receptor antagonist VML 588.
- 1 August 2003
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 18 (8) , 1677-1678
Is coating of tubing required when endothelin-1 is infused intravenously?
- 1 August 2003
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 18 (8) , 1677-1678
Is coating of tubing required when endothelin-1 is infused intravenously?
- 1 January 1993
- Published by Royal Society of Chemistry (RSC) in Journal of Analytical Atomic Spectrometry
- Vol. 8 (4) , 611-614
Increased performance in electrothermal atomic absorption spectrometry of lithium in renal tubular fluid by use of tantalum foil
A method for the determination of lithium by electrothermal atomic absorption spectrometry in nanolitre samples of tubular fluid of rat kidneys was developed. The signal-to-noise ratio was improved by use of tantalum foil in the atomization step. Peak height absorbance increased ten times and integrated absorbance four times. The atomization temperature could be reduced by 300 °C. The sensitivity increased from 1.7 to 0.45 pmol, which permits the determination of lithium in 10 nl samples. Addition of lithium-free tubular fluid to lithium standards showed that no matrix effects were present and that background correction was not required. At a level of 0.25 mmol l–1, the within-day and between-day relative standard deviations (RSDs) were 5 and 4%, respectively. For plasma, the within-day and between-day RSDs were also 5 and 4%, respectively, at a level of 0.25 mmol l–1. The recovery of lithium standards added to plasma was 99 ± 4%. In untreated anaesthetized rats, the tubular fluid-to-plasma lithium concentration ratio for the late proximal part of the renal tubule was 1.10 ± 0.10 (mean ± SD; n= 180) and for the early distal part of the tubule 1.08 ± 0.13 (n= 102). Since tubular fluid-to-plasma concentration ratios can be assessed in both proximal and distal tubular fluid, the proposed method provides a tool to test whether lithium is a good marker of proximal tubular sodium reabsorption.
- 1 January 1993
- Published by Royal Society of Chemistry (RSC) in Journal of Analytical Atomic Spectrometry
- Vol. 8 (4) , 611-614
Increased performance in electrothermal atomic absorption spectrometry of lithium in renal tubular fluid by use of tantalum foil
A method for the determination of lithium by electrothermal atomic absorption spectrometry in nanolitre samples of tubular fluid of rat kidneys was developed. The signal-to-noise ratio was improved by use of tantalum foil in the atomization step. Peak height absorbance increased ten times and integrated absorbance four times. The atomization temperature could be reduced by 300 °C. The sensitivity increased from 1.7 to 0.45 pmol, which permits the determination of lithium in 10 nl samples. Addition of lithium-free tubular fluid to lithium standards showed that no matrix effects were present and that background correction was not required. At a level of 0.25 mmol l–1, the within-day and between-day relative standard deviations (RSDs) were 5 and 4%, respectively. For plasma, the within-day and between-day RSDs were also 5 and 4%, respectively, at a level of 0.25 mmol l–1. The recovery of lithium standards added to plasma was 99 ± 4%. In untreated anaesthetized rats, the tubular fluid-to-plasma lithium concentration ratio for the late proximal part of the renal tubule was 1.10 ± 0.10 (mean ± SD; n= 180) and for the early distal part of the tubule 1.08 ± 0.13 (n= 102). Since tubular fluid-to-plasma concentration ratios can be assessed in both proximal and distal tubular fluid, the proposed method provides a tool to test whether lithium is a good marker of proximal tubular sodium reabsorption.